





Growing pipeline across therapeutic areas




Information shown as of March 2025

2L: Second Line; R²: lenalidomide + rituximab; FL: Follicular Lymphoma; 1L: First Line; pLGG: pediatric Low-Grade Gliomas; PBC: Primary Biliary Cholangitis; PSC: Primary Sclerosing Cholangitis; FOP: Fibrodysplasia Ossificans Progressiva; Ax: Aesthetics; Tx: Therapeutics *Executed by Day One Pharmaceuticals ¹Registrational trial



Construire un portefeuille de produits à long terme



Informations en date de mars 2025

2L: seconde ligne; R2: légalidomide + rituximab; LF: lymphome folliculaire; 1L: première ligne; GBGp: gliomes de bas grade pédiatrique; AVB: atrésie des voies biliaires; CBP: cholangite biliaire primitive; CSP: cholangite sclérosante primitive; FOP: fibrodysplasie ossifiante progressive. *Sponsor: Day One Pharmaceuticals ¹ Etude pivotale pour enrégistrement.